(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > Facultad de Ciencias > Departamento de Histología y Anatomía Patológica > DA - Ciencias - HAP - Artículos de revista >

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
Autor(es) : Hsu, Y.F. (Y. F.)
Ajona, D. (Daniel)
Corrales, L. (Leticia)
Lopez-Picazo, J.M. (José M.)
Gurpide, A. (Alfonso)
Montuenga, L.M. (Luis M.)
Pio, R. (Rubén)
Palabras clave : Tumor markers
Lung cancer
Bronchoalveolar lavage
Sputum
Complement factor H
Diagnosis
Fecha incorporación: jun-2010
Editorial : Biomed Central
Versión del editor: http://dx.doi.org/10.1186/1476-4598-9-139
ISSN: 1476-4598
Cita: Hsu YF, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, et al. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 2010 Jun 7;9:139.
Resumen
Background Cetuximab, an antibody targeting the epidermal growth factor receptor (EGFR), increases survival in patients with advanced EGFR-positive non-small cell lung cancer when administrated in combination with chemotherapy. In this study, we investigated the role of complement activation in the antitumor mechanism of this therapeutic drug. Results EGFR-expressing lung cancer cell lines were able to bind cetuximab and initiate complement activation by the classical pathway, irrespective of the mutational status of EGFR. This activation led to deposition of complement components and increase in complement-mediated cell death. The influence of complement activation on the activity of cetuximab in vivo was evaluated in xenografts of A549 lung cancer cells on nude mice. A549 cells express wild-type EGFR and have a KRAS mutation. Cetuximab activity against A549 xenografts was highly dependent on complement activation, since complement depletion completely abrogated the antitumor efficacy of cetuximab. Moreover, cetuximab activity was significantly higher on A549 cells in which a complement inhibitor, factor H, was genetically downregulated. Conclusions We demonstrate for the first time that the in vivo antitumor activity of cetuximab can be associated with a complement-mediated immune response. These results may have important implications for the development of new cetuximab-based therapeutic strategies and for the identification of markers that predict clinical response.
Enlace permanente: http://hdl.handle.net/10171/13051
Aparece en las colecciones: DA - CIMA - Oncología - Biomarcadores - Artículos de Revista
DA - Ciencias - HAP - Artículos de revista

Ficheros en este registro:
Fichero:  HsuMolCanc2010_9_139.pdf
Descripción: 
Tamaño:  748,6 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.